| [1] |
Jeng W, Lok AS. What will it take to cure hepatitis B?[J]. Hepatol Commun,2023,7(4):e84.
|
| [2] |
Chang J, Block TM, Guo J. The innate immune response to hepatitis B virus infection: Implications for pathogenesis and therapy[J]. Antiviral Res,2012,96(3):405-413.
|
| [3] |
Li Q, Sun B, Zhuo Y, et al. Interferon and interferon-stimulated genes in HBV treatment[J]. Front Immunol,2022,13(1):1034968.
|
| [4] |
Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses[J]. Annu Rev Immunol,2014,32(10):513-545.
|
| [5] |
Yang G, Wan P, Zhang Y, et al. Innate Immunity, Inflammation, and Intervention in HBV Infection[J]. Viruses,2022,14(10):2275.
|
| [6] |
Han Q, Zhang C, Zhang J, et al. The role of innate immunity in HBV infection[J]. Semin Immunopathol,2013,35(1):23-38.
|
| [7] |
Du Y, Wu J, Liu J, et al. Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection[J]. Front Immunol,2022,13:965018.
|
| [8] |
Duan T, Du Y, Xing C, et al. Toll-like receptor signaling and its role in cell-mediated immunity[J]. Front Immunol,2022,13:812774.
|
| [9] |
Yuen M, Balabanska R, Cottreel E, et al. TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial[J]. Lancet Infect Dis,2023,23(4):496-507.
|
| [10] |
Amin OE, Colbeck EJ, Daffis S, et al. Therapeutic potential of TLR8 agonist GS‐9688 (selgantolimod) in chronic hepatitis B: remodeling of antiviral and regulatory mediators[J]. Hepatology,2021,74(1):55-71.
|
| [11] |
Gane EJ, Kim HJ, Visvanathan K, et al. Safety, pharmacokinetics, and pharmacodynamics of the oral TLR8 agonist selgantolimod in chronic hepatitis B[J]. Hepatology,2021,74(4):1737-1749.
|
| [12] |
Reyes M, Lutz JD, Lau AH, et al. Safety, Pharmacokinetics and pharmacodynamics of selgantolimod, an oral Toll-like receptor 8 agonist: A phase Ⅰa study in healthy subjects[J]. Antivir Ther,2020,25(3):171-180.
|
| [13] |
Vajjhala PR, Ve T, Bentham A, et al. The molecular mechanisms of signaling by cooperative assembly formation in innate immunity pathways[J]. Mol Immunol,2017,86:23-37.
|
| [14] |
Nahavandi-Parizi P, Kariminik A, Montazeri M. Retinoic acid-inducible gene 1 (RIG-1) and IFN-β promoter stimulator-1 (IPS-1) significantly down-regulated in the severe coronavirus disease 2019 (COVID-19)[J]. Mol Biol Rep,2023,50(1):907-911.
|
| [15] |
Yuen M, Chen C, Liu C, et al. A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B[J]. Liver Int,2023,43(1):77-89.
|
| [16] |
Agarwal K, Afdhal N, Coffin C, et al. LBP04--Liver toxicity in the phase 2 catalyst 206 trial of Inarigivir 400 mg daily added to a nucleoside in HBV EAg negative patients[J]. J Hepatol,2020,73:S125.
|
| [17] |
Kuipery A, Gehring AJ, Isogawa M. Mechanisms of HBV immune evasion[J]. Antiviral Res,2020,179:104816.
|
| [18] |
Markham A. Envafolimab: First approval[J]. Drugs,2022,82(2):235-240.
|
| [19] |
Zhang F, Wei H, Wang X, et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade[J]. Cell Discov,2017, 3(1):17004.
|
| [20] |
Gane E, Verdon DJ, Brooks AE, et al. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study[J]. J Hepatol,2019, 71(5):900-907.
|
| [21] |
Wu T, Stevens S, Liu C, et al. Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B[J]. J Hepatol,2022,77:S853.
|
| [22] |
Wang G, Qian J, Cui Y, et al. A phase Ⅱa trial of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) in patients with chronic hepatitis B[J]. 2021.Oral abstracts 91.
|
| [23] |
Meng Z, Chen Y, Lu M. Advances in Targeting the innate and adaptive immune systems to cure chronic hepatitis B virus infection[J]. Front Immunol,2020,10:3127.
|
| [24] |
Kruse RL, Shum T, Tashiro H, et al. HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice[J]. Cytotherapy,2018,20(5):697-705.
|
| [25] |
Guo G, He W, Zhou Z, et al. PreS1-targeting chimeric antigen receptor T cells diminish HBV infection in liver humanized FRG mice[J]. Virology,2023,586:23-34.
|
| [26] |
Ebert G, Allison C, Preston S, et al. Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis[J]. PANS,2015,112(18): 803-5808.
|
| [27] |
Liu H, Hou J, Zhang X. Targeting cIAPs, a new option for functional cure of chronic hepatitis B infection?[J]. Virol Sin,2018,33(5):459-461.
|
| [28] |
Al Mahtab M, Akbar SMF, Yoshida O, et al. Antiviral response across genotypes after treatment of chronic hepatitis B patients with the therapeutic vaccine NASVAC or pegylated interferon[J]. Vaccines (Basel),2023,11(5):962.
|
| [29] |
Al Mahtab M, Akbar SMF, Aguilar JC, et al. Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase Ⅲ clinical trial)[J]. PLoS One,2018,13(8):e201236.
|
| [30] |
Yoshida O, Akbar S, Imai Y, et al. Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow-up results of phase IIa clinical study[J]. Hepatol Res,2023,53(3):196-207.
|
| [31] |
Al-Mahtab M, Akbar SMF, Aguilar JC, et al. Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment[J]. Front Med,2023,10:1032531.
|
| [32] |
Wei L, Zhao T, Zhang J, et al. Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trial[J]. Hepatology,2022,75(1):182-195.
|
| [33] |
Su J, Brunner L, Ates Oz E, et al. Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models[J]. J Hepatol,2023,78(4):717-730.
|
| [34] |
Kosinska AD, Festag J, Mück-Häusl M, et al. Immunogenicity and antiviral response of therapeutic hepatitis B vaccination in a mouse model of HBeAg-negative, persistent HBV infection[J]. Vaccines,2021,9(8):841.
|
| [35] |
Bunse T, Kosinska AD, Michler T, et al. PD-L1 silencing in liver using siRNAs enhances efficacy of therapeutic vaccination for chronic hepatitis B[J]. Biomolecules,2022,12(3):470.
|